196 related articles for article (PubMed ID: 15592575)
1. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.
Yoshida K; Kohzuki M
Cardiovasc Drug Rev; 2004; 22(4):285-308. PubMed ID: 15592575
[TBL] [Abstract][Full Text] [Related]
2. Olmesartan medoxomil.
Warner GT; Jarvis B
Drugs; 2002; 62(9):1345-53; discussion 1354-6. PubMed ID: 12076183
[TBL] [Abstract][Full Text] [Related]
3. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
4. Olmesartan medoxomil: current status of its use in monotherapy.
Brunner HR
Vasc Health Risk Manag; 2006; 2(4):327-40. PubMed ID: 17323586
[TBL] [Abstract][Full Text] [Related]
5. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
Gardner SF; Franks AM
Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
[TBL] [Abstract][Full Text] [Related]
6. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Stumpe KO
Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
Chrysant SG; Marbury TC; Robinson TD
J Hum Hypertens; 2003 Jun; 17(6):425-32. PubMed ID: 12764406
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.
Malacco E; Omboni S; Mallion JM; Volpe M;
High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):213-22. PubMed ID: 23430666
[TBL] [Abstract][Full Text] [Related]
10. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives.
Ball KJ; Williams PA; Stumpe KO
J Hypertens Suppl; 2001 Jun; 19(1):S49-56. PubMed ID: 11451215
[TBL] [Abstract][Full Text] [Related]
11. Olmesartan medoxomil: a review of its use in the management of hypertension.
Scott LJ; McCormack PL
Drugs; 2008; 68(9):1239-72. PubMed ID: 18547134
[TBL] [Abstract][Full Text] [Related]
12. Olmesartan medoxomil evaluated for safety and efficacy in Indian patients with essential hypertension: a real world observational postmarketing surveillance.
Rana R; Singh A
J Assoc Physicians India; 2010 Feb; 58():77-83. PubMed ID: 20653147
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs.
Stumpe KO; Ludwig M
J Hum Hypertens; 2002 May; 16 Suppl 2():S24-8. PubMed ID: 11967729
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.
Kereiakes DJ; Neutel JM; Punzi HA; Xu J; Lipka LJ; Dubiel R
Am J Cardiovasc Drugs; 2007; 7(5):361-72. PubMed ID: 17953475
[TBL] [Abstract][Full Text] [Related]
15. Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.
Kawai T; Takei I; Shimada A; Hirata T; Tanaka K; Saisho Y; Irie J; Horimai C; Matsumoto H; Itoh H
Clin Drug Investig; 2011; 31(4):237-45. PubMed ID: 21184621
[TBL] [Abstract][Full Text] [Related]
16. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
Brunner HR
J Hum Hypertens; 2002 May; 16 Suppl 2():S13-6. PubMed ID: 11967728
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].
Sada T; Mizuno M
Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):257-69. PubMed ID: 15467259
[TBL] [Abstract][Full Text] [Related]
18. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
Omboni S; Malacco E; Mallion JM; Volpe M
Drugs Aging; 2012 Dec; 29(12):981-92. PubMed ID: 23179896
[TBL] [Abstract][Full Text] [Related]
19. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
[TBL] [Abstract][Full Text] [Related]
20. Olmesartan medoxomil: an angiotensin II-receptor blocker.
Brousil JA; Burke JM
Clin Ther; 2003 Apr; 25(4):1041-55. PubMed ID: 12809956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
